<DOC>
	<DOCNO>NCT02824094</DOCNO>
	<brief_summary>Primary objective study allow access evaluate safety crizotinib patient Japan advance NSCLC harbor translocation inversion involve ROS1 oncogene .</brief_summary>
	<brief_title>Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Histologically cytologically proven diagnosis NSCLC locally advance metastatic . Positive translocation inversion event involve ROS1 gene determine protocol define test . ECOG performance status 0 2 . Adequate organ function Patients brain metastasis eligible neurologically stable least 2 week ongoing requirement corticosteroid . Male patient able father child female patient childbearing potential risk pregnancy must agree use 2 highly effective method contraception throughout study least 90 day last dose crizotinib . Currently receive crizotinib investigational product . Prior therapy specifically direct ROS1 fusion gene include crizotinib . Carcinomatous meningitis leptomeningeal disease . Spinal cord compression unless treat patient attain good pain control stable recover neurologic function . Ongoing uncontrolled congestive heart failure ( CHF ) follow within 3 month prior start study treatment : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , cerebrovascular accident include transient ischemic attack . Ongoing cardiac dysrhythmias CTCAE Grade 2 , uncontrolled atrial fibrillation grade , QTc 480 msec . History extensive disseminated/bilateral know presence Grade 3 4 interstitial fibrosis interstitial lung disease , include history pneumonitis , hypersensitivity pneumonitis , interstitial pneumonia , interstitial lung disease , obliterative bronchiolitis , pulmonary fibrosis , history prior radiation pneumonitis . Pregnant female patient ; breastfeed female patient . Use drug food include know potent CYP3A4 inhibitor , know potent CYP3A4 inducer CYP3A4 substrates narrow therapeutic index</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Expanded Access Protocol</keyword>
	<keyword>crizotinib</keyword>
	<keyword>Xalkori</keyword>
	<keyword>ROS1</keyword>
	<keyword>Japanese</keyword>
	<keyword>A8081064</keyword>
</DOC>